A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin

1996 ◽  
Vol 59 (1) ◽  
pp. 12-16 ◽  
Author(s):  
K. Overgaard ◽  
C. Christiansen
Keyword(s):  
Bone Resorption ◽  
Salmon Calcitonin ◽  
Biochemical Marker ◽  
Nasal Salmon Calcitonin

Acute changes in bone resorptive and formative markers after nasal salmon calcitonin

1992 ◽  
Vol 17 ◽  
pp. 157
Author(s):  
G. Thamsborg ◽  
S. Skousgaard ◽  
G. Kollerup ◽  
O.H. Sørensen
Keyword(s):  
Salmon Calcitonin ◽  
Nasal Salmon Calcitonin ◽  
Acute Changes

scholarly journals Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies

Blood ◽  
1996 ◽  
Vol 87 (11) ◽  
pp. 4762-4769 ◽  
Author(s):  
R Bataille ◽  
D Chappard ◽  
MF Basle
Keyword(s):  
High Risk ◽  
Bone Resorption ◽  
Monoclonal Gammopathy ◽  
Plasma Cells ◽  
Bone Biopsy ◽  
Low Risk ◽  
Early Symptom ◽  
Major Interest ◽  
Bone Biopsies

To determine if excessive osteoclastic-mediated bone resorption (BR) is an early tumor-induced event in multiple myeloma (MM), BR was assessed at first presentation on quantitative bone biopsy in 87 individuals evaluated for monoclonal gammopathy of undetermined significance (MGUS) and reinterpreted according to the presenting features and subsequent follow-up evaluation. As a reference population, 48 patients with previously untreated overt MM were evaluated under similar conditions. The median level of BR was significantly higher in 48 overt MM versus 87 MGUS patients (12.2% v 5.1% [normal level, <6%], P <.01). Actually, 93% of overt MM patients had an excessive BR versus 45% of MGUS patients at presentation (P <.01) According to simple presenting parameters (> or <5% plasma cells within the bone marrow, presence or absence of mild anemia/neutropenia), 31 individuals were classified as low-risk MGUS, 32 high-risk MGUS, and 24 indolent MM. An excessive BR was observed in 16% of low-risk MGUS, 46% of high-risk MGUS (P <.01 v low-risk MGUS), 79% of indolent MM (P <.05 v high-risk MGUS), and 93% of overt MM patients. Of major interest, the level of BR in indolent MM (11.2%) was identical to that in overt MM (12.2%) but significantly higher than in both low-risk (4%, P <.01) and high-risk (5.6%, P <.01) MGUS. When considering the follow-up evaluation of MGUS patients, an excessive BR at presentation was observed in 52% of MGUS cases that turned out to be unstable or developed subsequent MM, but in only 4% of stable MGUS (P <.01). More precisely the level of BR of low-risk MGUS that either turned out to be unstable or that developed into MM was significantly higher at presentation than that of subsequent stable MGUS (4.4% v 2.9%, P <.05). The same difference was observed in both high-risk MGUS and indolent MM according to subsequent follow-up studies (8.1% v 3.4% and 11.7% v 6%, respectively, P <.05). Of major interest, the level of BR in 11 stable high-risk MGUS cases actually fulfilling the diagnostic criteria of smoldering MM was very low (3.4%) and similar to that in stable low-risk MGUS (2.9%). We conclude that a quantifiable excess of BR in MGUS is significantly associated with progression and thus is an early symptom of malignancy in these individuals.

Salmon Calcitonin and the Treatment of Acute Osteoporosis

2006 ◽  
Vol 00 (02) ◽  
Author(s):  
Harold N Rosen
Keyword(s):  
Vertebral Fracture ◽  
Bone Resorption ◽  
Bone Formation ◽  
Salmon Calcitonin ◽  
Analgesic Effect ◽  
Treatment Options ◽  
Vertebral Compression Fractures ◽  
Human Calcitonin ◽  
Older Individuals ◽  
Compression Fractures

There are many different treatment options for osteoporosis available to physicians. Most of these are designed to prevent and treat osteoporosis by inhibiting bone resorption and/or increasing bone formation. One group of patients with very specific needs is those with vertebral compression fractures especially in those whom the most commonly used treatment, bisphosphonate, is not well tolerated. Under these circumstances salmon calcitonin, a treatment that has known efficacy in reducing further vertebral fracture, an analgesic effect, and is known to be safe and well tolerated in older individuals, could be the answer.Salmon calcitonin is the most widely used of the calcitonins effective in humans. It has 40 times the affinity for osteoclasts as human calcitonin and is very effective at inhibiting bone resorption.1,2

Evaluation of bone resorption in fibula and deep circumflex iliac artery flaps following dental implantation: A three-year follow-up study

2017 ◽  
Vol 45 (4) ◽  
pp. 474-478 ◽  
Author(s):  
Kristian Kniha ◽  
Stephan Christian Möhlhenrich ◽  
Ann Christina Foldenauer ◽  
Florian Peters ◽  
Nassim Ayoub ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Iliac Artery ◽  
Follow Up Study ◽  
Dental Implantation ◽  
Deep Circumflex Iliac Artery

Composite Osteocutaneous Groin Flap Combined with Neurovascular Island Flap for Thumb Reconstruction

2003 ◽  
Vol 28 (5) ◽  
pp. 399-404 ◽  
Author(s):  
F. PARMAKSIZOGLU ◽  
T. BEYZADEOGLU
Keyword(s):  
Bone Resorption ◽  
Functional Results ◽  
Metacarpophalangeal Joint ◽  
Island Flap ◽  
Bone Block ◽  
Thumb Reconstruction ◽  
Groin Flap ◽  
Three Phase ◽  
Bone Scans

Three amputated thumbs were reconstructed with a composite osteocutaneous groin flap and a neurovascular island flap. The average age at the time of surgery was 28 (range 25–35) years. The level of the amputation was distal to metacarpophalangeal joint in two cases and proximal in one case. The injury mechanism was avulsion in all cases. The postoperative follow-up periods ranged from 27 to 30 months. There were no cases of skin necrosis, bone resorption or infection. Radiographs and three-phase bone scans showed union of the iliac bone block and the stump without any resorption in all three patients. This surgical procedure is reliable and simple and the functional results are satisfying. We reserve this technique for the treatment of thumb amputations which cannot be replanted, particularly as it does not result in bone resorption.

Sign in / Sign up

Export Citation Format

Share Document